Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Not all companies are worth the risk, and that’s why we built StockStory - to help you spot the red flags. Keeping that in mind, here is one high-risk, high-reward company with the potential to scale into a market leader and two that may struggle to stay afloat.
Two Stocks to Sell:
Krispy Kreme (DNUT)
Trailing 12-Month Free Cash Flow Margin: -4.2%
Famous for its Original Glazed doughnuts and parent company of Insomnia Cookies, Krispy Kreme (NASDAQ: DNUT) is one of the most beloved and well-known fast-food chains in the world.
Why Are We Out on DNUT?
- Earnings per share have contracted by 21.6% annually over the last four years, a headwind for returns as stock prices often echo long-term EPS performance
- Cash-burning history makes us doubt the long-term viability of its business model
- Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution
At $3.83 per share, Krispy Kreme trades at 154.7x forward P/E. Dive into our free research report to see why there are better opportunities than DNUT.
PacBio (PACB)
Trailing 12-Month Free Cash Flow Margin: -71.2%
Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ: PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness.
Why Are We Wary of PACB?
- Sales tumbled by 10.7% annually over the last two years, showing market trends are working against its favor during this cycle
- Cash burn makes us question whether it can achieve sustainable long-term growth
- Unprofitable operations could lead to additional rounds of dilutive equity financing if the credit window closes
PacBio is trading at $1.57 per share, or 2.8x forward price-to-sales. Read our free research report to see why you should think twice about including PACB in your portfolio.
One Stock to Watch:
Rocket Lab (RKLB)
Trailing 12-Month Free Cash Flow Margin: -53.5%
Becoming the first private company in the Southern Hemisphere to reach space, Rocket Lab (NASDAQ: RKLB) offers rockets designed for launching small satellites.
Why Do We Like RKLB?
- Annual revenue growth of 56.9% over the last two years was superb and indicates its market share increased during this cycle
- Market share will likely rise over the next 12 months as its expected revenue growth of 42.6% is robust
- Rising returns on capital show the company is starting to reap the benefits of its past investments
Rocket Lab’s stock price of $78.79 implies a valuation ratio of 54.9x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
